Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Panitumumab, Nivolumab, and Ipilimumab in Refractory mCRC
NCT03442569Phase 2Completed
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
- Start
- Mar 2018
- Primary completion
- Sep 2020
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of panitumumab, nivolumab, ipilimumab in colorectal cancer (CRC), sponsored by UNC Lineberger Comprehensive Cancer Center. Started Mar 2018; status: completed.
02
Drugs
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT03442569.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03442569.